Rett Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Rett syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of Rett syndrome for each country, as well as annualized case counts projected to the national population.
We forecast over a period of 20 years for these markets.
Clarivate Epidemiology’s Rett syndrome forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Rett syndrome over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts three Rett syndrome patient populations, as follows:
- Diagnosed prevalent cases of Rett syndrome.
- Diagnosed prevalent cases of classical Rett syndrome.
- Diagnosed prevalent cases of atypical Rett syndrome.
Note: Coverage may vary by country.
